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Abstract
There is growing evidence that TNF-alpha and its two receptors play an important role in hormonal regulation, metabolism, 
inflammation and cancer. The biological effects of TNF-alpha are mediated by two receptors, p55 and p75. The aim of this 
study was to analyze serum concentrations of p55 and p75 and hormonal status in healthy women during the normal 
menstrual cycle. Eight women aged 20–22 with regular menstrual cycles were scheduled for examination on 3rd, 8th, 14th 
and 25th day of their menstrual cycle. We only observed a positive correlation of p75 subunit with prolactin level (correlation 
coefficient 0.417; p=0.0116) and negative correlation with insulin level (correlation coefficient -0.35; p=0.032) and HOMAIR 
insulin resistance index correlation coefficient 0.39; p=0.0185). Furthermore, a negative correlation of p55/p75 ratio with 
prolactin (correlation coefficient -0.42; p=0.0101) and a positive correlations of p55/p75 ratio with insulin level (correlation 
coefficient 0.43; p=0.008) and HOMAIR insulin resistance factor correlation coefficient 0.45; p=0.0065) were found.
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INTRODUCTION
Sex and gender differences in prevalence of different 
disease, pathogenesis and modulation have been frequently 
reported. The menstrual cycle represents one of most 
important factors which should be considered during study 
of the physiological effect of hormonal fluctuations and the 
immune function, as well as chronic disease modulation. 
The effect of the cycle on immune cell numbers and activity 
fluctuations have not often been reported in studies, but 
recent publications demonstrate an increasing interest in 
the subject. The menstrual cycle might affect immune cell 
numbers and modulate their activity throughout the 4-week 
cycle, as demonstrated in the case of regulatory T cells. The 
importance of these fluctuations are particularly relevant 
in the chronic diseases affecting women of reproductive 
age. The inflammation and immune cell activation in 
association with other mechanisms, such as regulation of 
receptor expression, modulation of muscular contraction and 
behavioural aspects might explain the menstrual-associated 
fluctuations known in many diseases. The modulatory effects 
of the menstrual cycle on both immune cells and systemic 
diseases, such as autoimmune diseases, asthma, diabetes, 
cardiac arrhythmia and schizophrenia, has been reported. 
Most of these diseases display worsening of symptoms 
premenstrually or during menses due to physiologic effects 
on the target tissue mediated by progesterone and estrogen 
fluctuations and, thus, display important changes potentially 
relevant to numerous other conditions [1]. Menstrual cycles 
act as evident indicators of underlying reproductive health, 
i.e. infertility and increases future risk of various chronic 
diseases. Dysfunctional menstrual cycles can begin from 
adolescence and persist for many years and throughout 
reproductive life, causing physical, psychological, and 
economical strains on a women’s life. Menstrual length has 
been used as good marker of ovarian steroid production and 
its regularity is a marker of smooth function of hypothalamus 
pituitary ovarian axis. The average menstrual bleeding is 
about 7 days, and the range could be between 3–10 days. Many 
environmental factors may affect the characteristics of the 
menstrual cycle including workplace, caffeine consumption, 
smoking, occupation, physical activity, diet, age, weight, 
exposure to organic solvent, medical conditions, and lifestyle 
factors. Shayesteh found that both irregular menstruation 
and abnormal menstrual amount were connected with 
environmental effects. The heritability value for menstrual 
characteristic were less than 0.1% for interval, and were 
about 2% for duration; further analysis suggested that 95% 
of non-shared environmental effect for interval and 67% of 
shared environmental effect for duration [2].
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The menstrual cycle is a series of cyclic physiological 
changes that occur in the fertile human female as well as 
in some primate females. It is a highly complex process 
involving close hormonal interaction between the 
hypothalamus, the hypophysis and the ovary. Within the 
menstrual cycle, ovarian, endometrial and cervical cycle 
can also be distinguished. In addition to hormonal feedback 
mechanisms, there is also a variety of cytokines and growth 
factors that regulate ovarian and endometrial changes on the 
cellular level [3]. Among these substances, Tumour Necrosis 
Factor-alpha (TNF-α) has become of special interest.
TNF-α is a well known member of TNF superfamily 
involved in numerous cellular processes, such as regulation 
of cell survival, apoptosis, migration and differentiation. 
Numerous, both physiological and pathological functions of 
TNF-alpha, have been described. In the field of gynaecology, 
numerous authors describe its pivotal role in the physiology 
of the ovary and endometrial function [4, 5]. TNF-α is 
also involved in several gynaecological pathologies, such 
as ovarian and endometrial cancer, endometriosis and 
infertility [4, 6, 7, 8, 9].
The biological effects of TNF-α are mediated by its two 
receptors, namely p55 (CD120a; TNFR1) and p75 (CD120b; 
TNFR2). Upon binding to these receptors the signal is 
transferred into the cell to target transcription proteins: 
Nuclear Factor Kappa B (NFκB) and c-Jun, which initiate 
transcriptional changes [4]. This results in activation of DNA 
regions responsible for cell growth, death and inflammatory 
response [9]. Both receptors are present on virtually any 
cell of higher mammals. Current data indicate that TNFR1 
signals for all known activities of TNF-α, including apoptosis, 
differentiation and proliferation, while TNFR2 seems to 
signal rather metabolic actions. Relative expression and 
concentration of selected receptors might also shape the final 
response to TNF-α [10].
Cell-bound TNF-α receptors are able to dissociate from 
the cell surface and become active in the serum [11]. These 
soluble receptors (sTNFRs) are able to bind TNF-α in the 
blood stream, thereby blocking its biological effects. On the 
other hand, sTNFRs stabilize TNF-α activity by creating a 
slow release reservoir for TNF-α by impeding spontaneous 
denaturation of the cytokine [12]. Althought the exact role 
of sTNFRs remains unknown, several studies, among them 
also ours, describe varying concentrations of both soluble 
and cell bound p55 and p75 concentrations in patients with 
benign and malignant ovarian tumours [13, 14, 15, 16, 17] 
or infertility [18]. Furthermore, sTNFRs are more stable and 
easier to measure than TNF-α, thereby becoming attractive 
subjects for diagnostic analysis [12].
TNF-α is also critically involved in the physiology of 
menstrual cycle [4]. The concentration of TNF-α mRNA in 
endometrial tissue varies across the cycle and peaks in the 
proliferative phase [13,20]. Additionally, local expression of 
its receptors varies across the cycle. TNFR1 peaks in the late 
secretory phase [13]. TNFR2 has a slightly different expression 
pattern with highest levels in the late proliferative and late 
secretory phases [19]. To the best of our knowledge, there is 
no available data concerning changes of serum free TNFRs in 
the menstrual cycle. The aim of this study, therefore, was to 
analyze serum concentrations of p55 and p75 and hormonal 
status in healthy women during the normal menstrual cycle.
MATERIALS AND METHOD
The study was performed between 1 November – 20 
December 2009. Eight healthy Caucasian female volunteers 
aged 20–22 (BMI 20.2–25.4 kg/m2) were enrolled in the study. 
The inclusion criteria consisted of regular menstrual cycles 
(27–29 days), negative history of menstrual or hormonal 
disorders or therapies, no actual contraception and no 
serious disease for at least 3 months before the beginning 
of the study. All females were nulliparous, with no medical 
chronic disease or neoplasm in anamnesis. All patients 
were scheduled for 4 visits dated exactly on 3rd, 8th, 14th and 
25th day of their menstrual cycle. The days were chosen 
based on physiological changes: early and late follicular 
phase, paraovulatory time and luteal phase. During every 
follow-up visit blood was collected and routine hormonal 
analysis performed for follicle-stimulating hormone (FSH), 
luteinizing hormone (LH), 17β-estadiol (E2), testosterone, 
sex hormone binding globulin (SHBG), DHEA-S, 
Thyroxine-stimulating hormone (TSH), free thyroxin and 
triiodothyronine (fT3, fT4) and prolactine. All hormones 
were estimated by electrochemiluminescence (ECLIA) on 
Roche C6000 (Hitachi, Japan) with maximum coefficients 
of 3.7% variations (reagents in routine laboratory processes). 
Based on glucose and insulin levels, the Insulin Resistance 
was calculated according to the HOMA (Homeostasis Mode 
Assessment) formula: HOMAIR=Insulin (μU/ml) x Glucose 
(mmol/l) / 22.5. Additionally, 5ml of blood was centrifuged 
for 5 min at 3,000 rpm to separate serum from morphotic 
elements. The serum was then stored at -20ºC until whole 
material was obtained. The concentrations of TNF-α, p55 
and p75 were assayed with commercially available kits 
(Quantakine, R and D Systems, USA) in duplicate. The 
extinction was read on Dynex MRX Endpoint 1.33 (UK). 
According to the manufacturer, the sensitivity of the p55 
and p75 tests were 3.0 pg/ml and 1.0 pg/ml, respectively. The 
intraassay precision did not exceed 8.2%.
Statistical analysis was performed using SigmaStat 
v3.1 software (Systat Inc., USA). For repeated measures, 
Friedmann Repeated Measures Analysis of Variance was 
used because the Kolgomorov-Smirnoff test failed to 
discover normal distribution. Data are presented as means 
+/– Standard Deviation. Correlations were evaluated with 
Spearman’s test (Rs). P value less than 0.05 was considered 
significant.
The study was approved by the Local Bioethics Committee.
RESULTS
The mean concentrations of TNF-α receptors on days 3, 8, 
14 and 25 are shown in Table 1. There were no statistically 
significant fluctuations of the p55 and p75 receptor 
concentrations during the menstrual cycle. Also, the p55/
p75 ratio did not change significantly throughout the cycle. 
The changes in hormonal levels are presented in Table 2.
Although no fluctuations of p55 and p75 receptors in a 
single menstrual cycle were found, the correlation between 
TNF-α receptors and selected serum biochemical parameters 
were evaluated. Almost no statistically significant correlation 
was found between either p55 or p75 or p55/p75 ratio and 
hormones (Tab. 3). Only a positive correlation of p75 subunit 
with prolactin level (Rs=0.417, p=0.0116) was observed, and 
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a negative correlation with insulin;level (Rs=-0.35; p=0.032) 
and HOMAIR insulin resistance index (Rs=-0.39; p=0.0185) 
(Tab. 2). Finally, a negative correlation of p55/p75 ratio with 
prolactin (Rs=-0.42; p=0.0101), as well a positive concentration 
of p55/p75 ratio with insulin level (Rs=0.43; p=0.008) and 
HOMAIR insulin resistency index (Rs=0.45; p=0.0065) were 
found (Tab. 3).
DISCUSSION
In the presented study, fluctuations of serum-free TNFRs 
across the female menstrual cycle were evaluated. According 
to this research, there were no changes in serum TNFR1 
level and TNFR1/TNFR2 ratio across the menstrual cycle. 
Only TNFR2 changes reached borderline significance. 
Interestingly, Fernandez-Real et al. described somewhat 
contradictory results, with sTNFRs levels changing during 
the menstrual cycle in most of lean women. Furthermore, the 
levels of these molecules remained unaltered in overweight 
women [21]. The changes of sTNFRs were observed in parallel 
to changes in leptin levels, which might indicate some 
correlation between TNF-signaling, obesity, and menstrual 
cycle.
This concept is particularly interesting in the context of 
our further biochemical analysis. A correlation between 
serum TNFR1 concentration and serum insulin levels, and 
HOMA-IR was found. The p55/p75 ratio also correlated 
positively with serum insulin levels and the HOMA-IR index. 
There are several factors that influence glucose homeostasis. 
In one aspect, insulin-sensitivity depends on the phase of 
the cycle. There is a decrease in insulin sensitivity in the 
luteal phase [22]. More detailed studies revealed a positive 
correlation of estrogen and progesterone with HOMA-IR 
across the menstrual cycle [23]. The presented data might 
indicate additional involvement of TNF-signaling in this 
phenomenon. In various studies, TNF-α was found to be 
crucial in the pathogenesis of insulin resistance [24, 25]. In 
overweight patients, TNF-α is upregulated in adipose and 
muscle tissue [26, 27]. Furthermore, treatment of some rodent 
diabetes models with soluble TNF-α receptor-Ig fusion 
protein led to reduction of insulin resistance [28]. Finally, 
various states characterized by increased levels of circulating 
TNF-α, such as infection or inflammatory diseases, also 
coincide with insulin resistance [29]. Upregulation of TNF-α 
was also found in gestational diabetes mellitus patients [30]. 
On the molecular level, TNF-α downregulates GLUT4 glucose 
transporter in adipocytes and myocytes [31]. Additionally, 
TNF produces serine phosphorylation of insulin receptor 
substrate-1, decreasing the tyrosine kinase activity of the 
insulin receptor [32]. The role of sTNFRs in the development 
of insulin resistance is not entirely clear. The presented study 
shows a slight negative correlation between sTNFR2 and 
insulin and insulin resistance index. In contrast, sTNFR1 did 
not correlate with either of these parameters. Data currently 
available in the literature support the presented observation 
[33]. Furthermore, sTNFR2 correlated with body-mass index 
(BMI), waist-hip ratio and fat-free mass – well-known 
cofounders in the evaluation of insulin sensitivity [34]. 
The presented findings and the findings of other authors 
support the involvement of TNF and its receptor systems 
in the regulation of glucose homeostasis, even in non-obese 
patients. But the current study focused on changes during 
the menstrual cycle; thus, the bias of obesity and insulin 
Table 3. Correlation between p55 and p75 TNF-receptor subunits and 
selected serum parameters
TNF receptors
parameter
receptor p55 receptor p75 p55/p75
TSH Rs=-0.07. p=0.673 Rs=0.03. p=0.838 Rs=-0.10. p=0.567
free T3 Rs=0.05. p=0.770 Rs=0.07. p=0.698 Rs=-0.06. p=0.732
free T4 Rs=-0.32. p=0.0545 Rs=-0.22. p=0.196 Rs=0.11. p=0.531
FSH Rs=-0.08. p=0.619 Rs=0.20. p=0.241 Rs=-0.27. p=0.109
LH Rs=-0.17. p=0.323 Rs=-0.25. p=0.136 Rs=0.22. p=0.201
Estradiol Rs=0.06. p=0.716 Rs=-0.17. p=0.329 Rs=0.18. p=0.284
Progesterone Rs=-0.01. p=0.954 Rs=0.004. p=0.979 Rs=-0.05. p=0.782
Prolactin Rs=0.16. p=0.351 Rs= 0.41. p=0.011 Rs=-0.42. p=0.010
Testosterone Rs=0.29. p=0.082 Rs=0.20. p=0.235 Rs=-0.17. p=0.316
Glucose Rs=-0.24. p=0.151 Rs=-0.20. p=0.244 Rs=0.19. p=0.263
Insulin Rs=0.02. p=0.98 Rs=-0.35. p=0.032 Rs=0.43. p=0.008
HOMAIR Rs=-0.04. p=0.79 Rs=-0.39. p=0.018 Rs=0.45. p=0.006
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Table 1. Serum concentrations of p55 and p75 receptors during the menstrual cycle
parameter 3rd day of menstrual cycle 8th day of menstrual cycle 14th day of menstrual cycle 25th day of menstrual cycle Fried man’s  test
P55 (pg/ml)
P75 (pg/ml)
P55/p75 ratio
  2.43 ± 1.41
20.20±20.60
 0.27±0.23
 1.78±0.98
13.50±17.93
 0.51±0.41
 2.58±1.36
14.95±16.44
 0.51±0.56
 2.06±0.94
15.13±16.14
 0.33±0.32
p=0.53
p=0.064
p=0.59
Table 2. serum concentrations of hormones
parameter 3rd day of menstrual cycle 8th day of menstrual cycle 14th day of menstrual cycle 25th day of menstrual cycle Fried man’s  test
TSH (uIU/Ml)
Free T3 (pg/mL)
Free T4 (ng/dL)
FSH (mIU/ml)
LH (mIU/ml)
Estradiol (pg/ml)
Progesterone (ng/mL)
Prolactin (ng/ml)
Testosterone (ng/ml)
Insulin (mU/mL)
Glucose (mg/dL)
HOMAIR
1.56 ±0.51
2.87±0.43
1.19±0.21
6.00±1.59
4.90±1.69
43.70±11.28
0.57±0.21
9.39±3.29
0.50±0.15
14.92±8.33
89.7±6.4
0.94±2.02
2.03±1.02
3.27±0.70
1.31±0.13
5.66±1.16
5.96±1.99
75.88±33.65
1.52±2.51
10.25±4.80
0.56±0.18
16.84±11.64
87.1±6.8
1.34±1.87
1.43±0.67
3.07±0.38
1.22±0.11
6.96±3.90
16.08±11.93
199.87±156.81
2.60±4.97
10.41±2.97
0.65±0.24
17.56±13.38
85.8±7.1
1.28±2.18
1.94±0.68
3.07±0.63
1.14±0.07
3.31±1.39
4.22±1.29
187.5±95.37
6.44±5.36
15.57±10.44
0.50±0.12
12.11±11.30
89.07±8.26
1.64±1.81
p=0.028
p=0.104
p=0.026
p=0.016
p=0.026
p<0.001
p=0.010
p=0.046
p=0.145
p=0.866
p=0.435
p=0.954
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resistance could be minimal regarding fluctuations in follow-
up subjects.
Another issue is the positive correlation between p75 
and negative between p55/p75 ratio with prolactin levels 
observed in the presented study. Prolactin is a peptide 
hormone secreted mainly by the anterior pituitary. It is 
considered a reproductive hormone, responsive mainly for 
milk production, but might also play an immunomodulatory 
role in inflammation [34]. Studies on the effect of TNF on the 
secretion of prolactin are conflicting. In animal experiments, 
some authors, e.g. Friedichsen and Koike showed an increase 
[35, 36], while Gaillard showed a decrease [37] or no effect 
(Milenkovic) [38] in PRL secretion upon treatment with TNF. 
In the current literature, however, there is some evidence 
concerning the link between prolactin regulation, estrogen 
and TNF signaling. In vivo, pituitary prolactin expression is 
regulated by dopamine and hypothalamic factors, such as 
TRH and plenty of intrapituitary factors [39]. In addition, 
estrogen is considered a major activator of prolactin synthesis 
and lactotroph proliferation [40]. Interestingly, the effects of 
estradiol on hPrl prolactin promoter gene are significantly 
amplified by TNF-a via the NFkB signaling pathway [35, 41]. 
Furthermore, estradiol increases expression of TNF-α and 
TNFR1 in lactotrope cells of the anterior pituitary [42]. All 
these data indicate a close relationship between estrogen, 
prolactin and TNF signaling pathways. Our data suggest 
that serum-free TNF receptors might also be involved in the 
regulation of prolactin secretion.
CONCLUSIONS
The levels of serum-free TNF receptors and p55/p75 ratio 
do not fluctuate significantly across the menstrual cycle. 
However, there is a correlation of p75 TNF receptor and 
p55/p75 ratio with insulin and prolactin levels and insulin 
resistance, which might indicate a new role of soluble TNF 
receptors in the human physiology. The limitation of the 
presented study is the small number of subjects. Some 
differences may not occur or are of borderline significance 
and need to be checked in further research. The potential 
information from this study is the understanding of TNF 
alpha receptors in the physiological status, which is the 
reference for considering pathologies iE ovarian cancer. 
We proved earlier that there are strong correlations and 
unspecific neoplastic answers, including TNF alpha receptors 
[15, 16, 17].
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